A precise understanding of the effect of these cytotoxic anti-cancer agents on NK cell viability/function directly, as well as on surface HLA-E kinetics and NK activating ligand expression on tumour cells will be required for optimal combination strategies. The gene discussed is HLA-E; the disease is neoplasm.